Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer
Go back to Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian Cancer| ALKERMES (NASDAQ: ALKS) | Delayed: 47.33 +1.31 (2.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $46.02 | 52 Week High | $80.71 | |||
| Open | $46.00 | 52 Week Low | $27.14 | |||
| Day High | $47.35 | P/E | 364.08 | |||
| Day Low | $45.47 | EPS | $0.13 | |||
| Volume | 497,336 | |||||
